“This second vaccine holds real potential to close the huge demand-and-supply gap,” said
WHO's regional director for Africa, Matshidiso Moeti.“Delivered to scale and rolled out …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …

We note the comments of Dr. Aaby [1] on 4 March 2009 regarding the use of control
vaccinations in our recent studies of RTS, S/AS01E in 5–17-month-old children [2] and RTS …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

See Articles page 1543 An effective vaccine would have tremendous benefit for the
estimated 3 billion people living at risk of malaria. In today's Lancet, John Aponte and …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …